LECT2 Ameliorates Blood–Retinal Barrier Impairment Secondary to Diabetes Via Activation of the Tie2/Akt/mTOR Signaling Pathway

Abstract

Purpose Current treatments for diabetic retinopathy (DR) have considerable limitations, emphasizing the need for new therapeutic options. The effect of leukocyte cell-derived chemotaxin 2 (LECT2) on diabetes-induced blood–retinal barrier impairment and the possible underlying mechanism were investigated both in vivo and in vitro. Methods Twenty diabetic and 22 nondiabetic eyes were included in this study. Additionally, we established a streptozotocin-induced diabetic mouse model and observed vascular leakage in mice treated with or without recombinant LECT2 (rLECT2) intravitreal injection (40 µg/mL, 1 µL). The levels of LECT2 and interendothelial junction proteins (ZO1, VE-cadherin, and occludin) were analyzed by western blot and/or immunofluorescence. Endothelial junctions in mouse retinas were observed by transmission electron microscopy (TEM). Moreover, confluent human retinal microvascular endothelial cells (HRMECs) and human umbilical vein endothelial cells (HUVECs) were treated (0–72 hours) with glucose (0 or 30 mM) in the presence or absence of rLECT2 (40–360 ng/mL). After treatment, intact cell monolayers were monitored for permeability to 40-kD FITC-dextran. Interendothelial junction targets and Tie2/Akt/mTOR signaling pathway components were investigated by western blot. Results In diabetic human and mouse retinas and high-glucose (30 mM)–treated HRMECs and HUVECs, the levels of LECT2 and interendothelial junction proteins were decreased. rLECT2 treatment (80 ng/mL) significantly attenuated the hyperglycemia-induced reduction in endothelial cell barrier function and inhibited the migration and tube formation of HRMECs and HUVECs. In addition, rLECT2 increased the levels of interendothelial junction proteins via activation of the Tie2/Akt/mTOR signaling pathway. Furthermore, intravitreal rLECT2 injections increased the levels of interendothelial junction proteins and reversed diabetes-induced junction disruption. Conclusions rLECT2 can increase the levels of interendothelial tight junction proteins through activation of the Tie2/Akt/mTOR signaling pathway and can ameliorate inner blood–retinal barrier impairment secondary to diabetes. LECT2 might be a potential target to prevent the progression of DR.

Low-Dose Trans-Resveratrol Ameliorates Diabetes-Induced Retinal Ganglion Cell Degeneration via TyrRS/c-Jun Pathway

“…The retina and cell proteins for Western blot were performed as previously described. 27 All the above samples were separated by SDS‒PAGE. The antibodies used are listed in Supplementary Table S1 .…”

The Protective Role of Apelin in the Early Stages of Diabetic Retinopathy

“…Vascular leakage was analyzed by intravenous injection of 100 μL tetramethylrhodamine isothiocyanate–dextran (1.5 mg/mL, 65 kD-85 kD, Sigma-Aldrich) 40 min before the eye harvest [ 30 ]. First, the eyeballs were fixed in 4% paraformaldehyde for 2 h at room temperature.…”

Effects of Lycium barbarum L. Polysaccharides on Vascular Retinopathy: An Insight Review

“…The BRB determines visual function and maintains the homeostasis of the retinal microenvironment by selectively regulating the molecular flux and substance exchange between the blood and retina [ 67 ]. The internal BRB (iBRB) are tightly connected by blood vessels and endothelial cells, and their functional properties depend on the molecular activity of tight junction proteins, including ZO-1/-2/-3, cadherin-5, cingulin, occluding, symplekin, claudins, and so on [ 68 , 69 , 70 ]. However, hyperglycemia can promote morphological changes in human retinal microvascular endothelial cells by transforming the growth factor -β1 (TGF-β1) and pro-inflammatory cytokines (IL-1β and TNF-α).…”